Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Hepatitis-Associated Aplastic Anemia, Alfadel Alshaibani, Carlo Dufour, Antonio Risitano, Regis De Latour, Mahmoud Aljurf
Hepatitis-Associated Aplastic Anemia, Alfadel Alshaibani, Carlo Dufour, Antonio Risitano, Regis De Latour, Mahmoud Aljurf
Hematology/Oncology and Stem Cell Therapy
Hepatitis-associated aplastic anemia (HAAA) is a rare illness, characterized by onset of pancytopenia with a hypoplastic bone marrow that traditionally occurs within 6 months of an increase in serum aminotransferases. HAAA is observed in 1% to 5% of all newly diagnosed cases of acquired aplastic anemia. Several hepatitis viruses have been linked to the disease, but in many cases no specific virus is detected. The exact pathophysiology is unknown; however, immune destruction of hematopoietic stem cells is believed to be the underlying mechanism. HAAA is a potentially lethal disease if left untreated. Management includes immunosuppression with antithymocyte globulin and cyclosporine …
Outcome Of Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation As A Treatment Option In Patients With Severe Aplastic Anemia Between 40 And 50 Years, Hosein Kamranzadeh Fumani, Mahdi Jalili, Soroush Rad, Davood Babakhani, Nasrollah Maleki, Seyed Asadollah Mousavi, Ardeshir Ghavamzadeh
Outcome Of Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation As A Treatment Option In Patients With Severe Aplastic Anemia Between 40 And 50 Years, Hosein Kamranzadeh Fumani, Mahdi Jalili, Soroush Rad, Davood Babakhani, Nasrollah Maleki, Seyed Asadollah Mousavi, Ardeshir Ghavamzadeh
Hematology/Oncology and Stem Cell Therapy
The frontline treatment for patients younger than 40 years with severe aplastic anemia (AA) is allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen-identical sibling donor. However, in patients with severe AA who are older than 40 years, allogeneic HSCT has been found to be associated with increased treatment related mortality and toxicity, even when matched sibling donors are used. We report our institutional experience with allogeneic HSCT in patients with severe AA between 40 and 50 years. A total of 19 patients with severe AA were included in the study. Overall survival (OS) and disease-free survival (DFS) …